Talis Biomedical Corp
NASDAQ:TLIS
Intrinsic Value
Talis Biomedical Corp. develops and commercialize innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. [ Read More ]
The intrinsic value of one TLIS stock under the Base Case scenario is 30.1443 USD. Compared to the current market price of 9.2002 USD, Talis Biomedical Corp is Undervalued by 69%.
Valuation Backtest
Talis Biomedical Corp
Run backtest to discover the historical profit from buying and selling TLIS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Talis Biomedical Corp
Current Assets | 89.5m |
Cash & Short-Term Investments | 88m |
Receivables | 5k |
Other Current Assets | 1.5m |
Non-Current Assets | 17.7m |
PP&E | 16.2m |
Other Non-Current Assets | 1.5m |
Current Liabilities | 8.5m |
Accounts Payable | 2.7m |
Accrued Liabilities | 5.8m |
Non-Current Liabilities | 17.2m |
Other Non-Current Liabilities | 17.2m |
Earnings Waterfall
Talis Biomedical Corp
Revenue
|
2.2m
USD
|
Cost of Revenue
|
-2.4m
USD
|
Gross Profit
|
-176k
USD
|
Operating Expenses
|
-77.5m
USD
|
Operating Income
|
-77.7m
USD
|
Other Expenses
|
2.2m
USD
|
Net Income
|
-75.5m
USD
|
Free Cash Flow Analysis
Talis Biomedical Corp
TLIS Profitability Score
Profitability Due Diligence
Talis Biomedical Corp's profitability score is 11/100. The higher the profitability score, the more profitable the company is.
Score
Talis Biomedical Corp's profitability score is 11/100. The higher the profitability score, the more profitable the company is.
TLIS Solvency Score
Solvency Due Diligence
Talis Biomedical Corp's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Talis Biomedical Corp's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TLIS Price Targets Summary
Talis Biomedical Corp
According to Wall Street analysts, the average 1-year price target for TLIS is 5 USD .
Ownership
TLIS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
TLIS Price
Talis Biomedical Corp
Average Annual Return | 44 798.7% |
Standard Deviation of Annual Returns | 63 479.82% |
Max Drawdown | -99% |
Market Capitalization | 16.7m USD |
Shares Outstanding | 1 821 990 |
Percentage of Shares Shorted | 1.14% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Talis Biomedical Corp. develops and commercialize innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Menlo Park, California. The company went IPO on 2021-02-12. (Talis) Is engaged in developing molecular diagnostic tests for infectious diseases at the point of care. The firm is focused on developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions. Talis is developing the Talis One platform, a cloud-enabled molecular diagnostic platform. The Talis One platform comprises a compact instrument, single-use test cartridges and software, including a central cloud database, which work together and are designed to provide central laboratory levels of accuracy. The platform is designed for use in non-laboratory settings, such as physicians’ offices, hospital emergency departments, urgent care clinics, ambulatory surgery centers, assisted living facilities, and cancer treatment and dialysis centers. The firm is also developing Talis One tests for respiratory infections, infections related to women’s health and sexually transmitted infections.
Contact
IPO
Employees
Officers
The intrinsic value of one TLIS stock under the Base Case scenario is 30.1443 USD.
Compared to the current market price of 9.2002 USD, Talis Biomedical Corp is Undervalued by 69%.